The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

Annals of the Rheumatic Diseases
Kevin L WinthropClifton O Bingham

Abstract

To evaluate tofacitinib's effect upon pneumococcal and influenza vaccine immunogenicity. We conducted two studies in patients with rheumatoid arthritis using the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) and the 2011-2012 trivalent influenza vaccine. In study A, tofacitinib-naive patients were randomised to tofacitinib 10 mg twice daily or placebo, stratified by background methotrexate and vaccinated 4 weeks later. In study B, patients already receiving tofacitinib 10 mg twice daily (with or without methotrexate) were randomised into two groups: those continuing ('continuous') or interrupting ('withdrawn') tofacitinib for 2 weeks, and then vaccinated 1 week after randomisation. In both studies, titres were measured 35 days after vaccination. Primary endpoints were the proportion of patients achieving a satisfactory response to pneumococcus (twofold or more titre increase against six or more of 12 pneumococcal serotypes) and influenza (fourfold or more titre increase against two or more of three influenza antigens). In study A (N=200), fewer tofacitinib patients (45.1%) developed satisfactory pneumococcal responses versus placebo (68.4%), and pneumococcal titres were lower with tofacitinib (particularly with methot...Continue Reading

References

Jul 3, 2004·Nature Reviews. Drug Discovery·John J O'SheaPaul S Changelian
Oct 14, 2004·Annals of the Rheumatic Diseases·J J O'shea
Oct 14, 2006·Annals of the Rheumatic Diseases·K L Winthrop
Jul 6, 2007·BMC Musculoskeletal Disorders·Evin Sowden, William S Mitchell
Sep 18, 2007·Best Practice & Research. Clinical Rheumatology·Kaleb Michaud, Frederick Wolfe
Feb 20, 2009·JAMA : the Journal of the American Medical Association·Anja StrangfeldAngela Zink
Jul 20, 2010·Arthritis Research & Therapy·Jeffrey R CurtisElizabeth Delzell
Feb 4, 2011·Annals of the Rheumatic Diseases·Karen AuUNKNOWN CORRONA Investigators
Apr 13, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter R Paradiso
Jul 27, 2012·Arthritis Care & Research·Jessica WiddifieldClaire Bombardier
Aug 10, 2012·The New England Journal of Medicine·Roy FleischmannUNKNOWN ORAL Solo Investigators
Aug 10, 2012·The New England Journal of Medicine·Ronald F van VollenhovenUNKNOWN ORAL Standard Investigators
Aug 14, 2012·Annals of the Rheumatic Diseases·Shunsuke MoriKazunori Oishi
Oct 16, 2012·Journal of Clinical Immunology·Robert A EisenbergKathleen E Sullivan
Jan 25, 2013·Annals of the Rheumatic Diseases·Shunsuke MoriKazunori Oishi
Jun 19, 2014·The New England Journal of Medicine·Eun Bong LeeUNKNOWN ORAL Start Investigators
Aug 27, 2014·Annals of the Rheumatic Diseases·Sheau-Pey WangYoshiya Tanaka

❮ Previous
Next ❯

Citations

May 20, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kunihiro Yamaoka
Jul 2, 2016·Zeitschrift für Rheumatologie·R Alten
Nov 9, 2016·Current Opinion in Immunology·Kiyoshi HiraharaJohn J O'Shea
Dec 13, 2017·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Claiton Viegas BrenolCarla Vizzotti
Sep 25, 2017·Arthritis Care & Research·Xavier MarietteMary G Boy
Nov 9, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Elisa V GomezDiane Phillips
Aug 24, 2017·Rheumatology and Therapy·Philipp Rein, Ruediger B Mueller
Nov 7, 2017·Nature Reviews. Drug Discovery·Daniella M SchwartzJohn J O'Shea
Nov 16, 2017·Drugs·Sohita Dhillon
Mar 17, 2018·The Journal of Rheumatology·Sujith SubesingheJames B Galloway
Nov 23, 2018·Journal of Cutaneous Medicine and Surgery·Kim A PappJohn Wade
Feb 27, 2019·Rheumatology·Massimo GadinaJohn J O'Shea
Feb 28, 2019·International Journal of Rheumatic Diseases·Chak Sing LauSwan Sim Yeap
Nov 19, 2019·Expert Opinion on Investigational Drugs·Jing WuChanghai Ding
Feb 29, 2020·Infection and Drug Resistance·Elaheh Kordzadeh-KermaniMohammadreza Salehi
Jun 21, 2017·Terapevticheskiĭ arkhiv·B S BelovD V Bukhanova
Jun 5, 2018·International Journal of Rheumatology·Ahmad AlEniziSawsan Hayat
Dec 4, 2015·Nature Reviews. Rheumatology·Daniella M SchwartzJohn J O'Shea
Aug 29, 2017·Arthritis & Rheumatology·Kevin L WinthropEustratios Bananis
Jan 27, 2021·The Journal of Dermatological Treatment·Jonathan RickVivian Y Shi
Jan 22, 2021·Nature Reviews. Gastroenterology & Hepatology·Ferdinando D'AmicoSilvio Danese
Feb 17, 2021·The Medical Clinics of North America·Cassandra Calabrese
Dec 20, 2020·Vaccines·Andrea ChiricozziGiampiero Girolomoni
Jan 22, 2021·Gut·Corey A SiegelUNKNOWN International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)
Jan 29, 2021·The Lancet. Gastroenterology & Hepatology·James L AlexanderUNKNOWN Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinica

❮ Previous
Next ❯

Methods Mentioned

BETA
antibody assay

Clinical Trials Mentioned

NCT01359150
NCT00413699

Software Mentioned

SAS

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.